Shannon N. Westin
Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer.
Overview
Shannon Westin is a gynaecologic oncologist and clinical trialist at MD Anderson Cancer Center. She was first author of the 2023 Journal of Clinical Oncology report of DUO-E, the phase 3 trial in which durvalumab with carboplatin and paclitaxel, followed by durvalumab with or without olaparib maintenance, improved progression-free survival in newly diagnosed advanced or recurrent endometrial cancer, with the largest benefit in mismatch repair-deficient tumours.
Similar pages
not linked directly; found by shared links- PersonVicky Makker
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tags endometrial, gynaecological, trialist.
- PersonAmanda Nickles Fader
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
- PersonAna Oaknin
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
- PersonDavid M. Gershenson
Shares MD Anderson Cancer Center, Ovarian cancer and the tags gynaecological, trialist.
- PersonMansoor Raza Mirza
Shares Endometrial cancer, Ovarian cancer and the tags endometrial, trialist.
- PersonRemi A. Nout
Shares Endometrial cancer and the tags endometrial, trialist.
- TrialHS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Ovarian cancer.
- TrialDUO-E / GOG-3041 / ENGOT-EN10
Shares DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer.